Alpha Bio Tec, Ltd. appears in FDA records as the applicant for K261295, a Traditional 510(k) for the MultiNeO Dental Implant System. The submission was received on 2026-04-20 and decided Substantially Equivalent on 2026-10-22, with a Summary statement and no third-party review. The device is classified as an endosseous root-form implant, class 2, dental specialty, under regulation 872.3640 and product code DZE. The applicant address on the filing is in Modi'In, Israel; that is a filing address, not a verified headquarters. [1][8][3]

The documented FDA record

The supplied collection holds one linked record, a 510(k) with a Substantially Equivalent decision, and the record sample contains that same single entry. These counts describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. The filing names Alpha Bio Tec, Ltd. as applicant, with Shani Aroch listed as contact, and identifies the device as the MultiNeO Dental Implant System under K261295. [1][8]

The FDA 510(k) final-decision listing for decisions rendered since October 01, 2026 includes K261295 with a Substantially Equivalent decision published 22 October 2026, consistent with the record-level decision date. The same product code, DZE, appears in that listing against other applicants' implant systems, which places the MultiNeO clearance within a shared regulatory category rather than a unique one. [3][8]

Product scope as published

Alpha Bio Tec's own MultiNeO page describes the MultiNeO implant as an implant designed for immediacy and carries the heading "Maximize on Immediacy." The company's dental implant solutions page organizes offerings under Products & Solutions, with a product catalog, distributor network, IFUs and a research and publications area. A company catalog states that Alpha Bio Tec's products are CE-marked under EU MDR 2017/745 and that the company complies with EN ISO 13485:2016, while noting product availability may vary between countries. [2][7][4]

The catalog's stated purpose is to provide simple workflows and easy-to-use implants, prosthetics and dental solutions. The website navigation lists regenerative solutions including bone graft and collagen membrane, alongside downloads, certificates, media and digital libraries. These are publisher descriptions of product categories; the public documents do not establish which specific items are commercially available in any given market. [4][5]

Published clinical research naming the implant

A controlled clinical trial indexed in PMC reports inserting 30 MultiNeO CS implants in a control group and 30 MultiNeO NH CS implants in a test group across 36 patients, in a study of a nano-superhydrophilic and bioactive surface in poor bone density. The article carries a correction published in 2024. The supplied excerpt documents the study's design and group sizes; it does not supply outcome figures, and none are restated here. [6]

Identity and attribution

The FDA record, the company website and the catalog all use the Alpha Bio Tec name, and the website presents MultiNeO within its implant solutions line. The public documents do not identify a parent company, brand owner or corporate group behind the applicant, so no ownership relationship is asserted. Contact details published on the company site include a telephone number and an info@alpha-bio.net address, attributed to the site operator. [1][2][5]